Skip to content
Nonprofiteer
← GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC

Form 990 for tax year 2023

Filed by GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC.

Totals

Total revenue
$60,240,486
Total expenses
$55,378,579
Contributions and grants received
$49,796,816
Grants paid
$278,450
Program service revenue
$0
Investment income
$8,182,816
Other revenue
$2,260,854
Total assets, end of year
$197,319,541
Total liabilities, end of year
$25,619,991
Net assets or fund balances, end of year
$171,699,550
Program services expenses (Part IX)
$48,843,533
Management and general expenses
$5,275,006
Fundraising expenses
$1,260,040
Program service expenses (Part III)
$48,843,533

Program services were 88.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1e · Government grants (contributions)

    $31,693,916

  • 1f · All other contributions, gifts and grants

    $18,102,900

  • 3 · Investment income

    total $8,060,173 · excluded $8,060,173

  • 4 · Income from investment of tax-exempt bond proceeds

    total $0

  • 5 · Royalties

    total $279,003 · excluded $279,003

  • 6c · Rental income or loss

    real property $0 · personal property $0

  • 6d · Net rental income or loss

    total $0

  • 7a · Gross sales of assets other than inventory

    securities $5,894,238

  • 7b · Less cost or other basis and sales expenses

    securities $5,771,595

  • 7c · Gain or loss

    securities $122,643

  • 7d · Net gain or loss

    total $122,643 · excluded $122,643

  • 8a · Fundraising events: gross income

    $0

  • 8b · Fundraising events: direct expenses

    $0

  • 8c · Net income from fundraising events

    total $0

  • 9a · Gaming: gross income

    $0

  • 9b · Gaming: direct expenses

    $0

  • 9c · Net income from gaming

    total $0

  • 10a · Gross sales of inventory

    $0

  • 10b · Cost of goods sold

    $0

  • 10c · Net income from sales of inventory

    total $0

  • 11a · Other revenue: MISCELLANEOUS INCOME

    total $1,981,851 · excluded $1,981,851

  • 11e · Other revenue, total

    $1,981,851

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $17,436 · program services $17,436

  • 2 · Grants to domestic individuals

    total $0

  • 3 · Grants to foreign organizations and individuals

    total $261,014 · program services $261,014

  • 4 · Benefits paid to or for members

    total $0

  • 5 · Compensation of officers, directors and key employees

    total $4,358,087 · program services $2,899,866 · management and general $1,172,864 · fundraising $285,357

  • 6 · Compensation of disqualified persons

    total $0

  • 7 · Other salaries and wages

    total $9,825,990 · program services $7,837,412 · management and general $1,471,173 · fundraising $517,405

  • 8 · Pension plan contributions

    total $917,447 · program services $736,623 · management and general $132,470 · fundraising $48,354

  • 9 · Other employee benefits

    total $1,516,953 · program services $1,202,330 · management and general $243,632 · fundraising $70,991

  • 10 · Payroll taxes

    total $747,089 · program services $569,880 · management and general $135,746 · fundraising $41,463

  • 11a · Fees: management

    total $0

  • 11b · Fees: legal

    total $794,479 · program services $746,167 · management and general $48,312

  • 11c · Fees: accounting

    total $135,690 · management and general $135,690

  • 11d · Fees: lobbying

    total $0

  • 11e · Fees: professional fundraising services

    total $0

  • 11f · Fees: investment management

    total $94,033 · management and general $94,033

  • 11g · Fees: other

    total $6,974,937 · program services $6,486,360 · management and general $417,379 · fundraising $71,198

  • 12 · Advertising and promotion

    total $0

  • 13 · Office expenses

    total $229,651 · program services $68,489 · management and general $159,776 · fundraising $1,386

  • 14 · Information technology

    total $1,087,453 · program services $443,412 · management and general $609,871 · fundraising $34,170

  • 15 · Royalties

    total $0

  • 16 · Occupancy

    total $787,118 · program services $575,190 · management and general $165,017 · fundraising $46,911

  • 17 · Travel

    total $1,174,079 · program services $897,298 · management and general $163,004 · fundraising $113,777

  • 18 · Travel or entertainment for public officials

    total $0

  • 19 · Conferences, conventions and meetings

    total $138,385 · program services $97,096 · management and general $41,289

  • 20 · Interest

    total $0

  • 21 · Payments to affiliates

    total $0

  • 22 · Depreciation, depletion and amortization

    total $186,444 · program services $136,435 · management and general $38,489 · fundraising $11,520

  • 23 · Insurance

    total $234,523 · program services $93,143 · management and general $141,380

  • 24a · Other expenses: R&D PROJECT EXPENSES

    total $25,704,187 · program services $25,704,187

  • 24b · Other expenses: DUES AND SUBSCRIPTIONS

    total $193,584 · program services $71,195 · management and general $104,881 · fundraising $17,508

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $0 · end of year $0

  • 2 · Savings and temporary cash investments

    beginning of year $159,750,193 · end of year $143,923,233

  • 3 · Pledges and grants receivable

    beginning of year $4,239,015 · end of year $1,821,719

  • 4 · Accounts receivable

    beginning of year $1,094,599 · end of year $1,102,554

  • 5 · Loans and receivables from officers and key people

    beginning of year $0 · end of year $0

  • 6 · Loans and receivables from disqualified persons

    beginning of year $0 · end of year $0

  • 7 · Other notes and loans receivable

    beginning of year $0 · end of year $0

  • 8 · Inventories for sale or use

    beginning of year $0 · end of year $0

  • 9 · Prepaid expenses and deferred charges

    beginning of year $1,057,756 · end of year $1,426,170

  • 10a · Land, buildings and equipment: cost or other basis

    $6,490,141

  • 10b · Land, buildings and equipment: accumulated depreciation

    $4,954,230

  • 10c · Land, buildings and equipment, net

    beginning of year $724,376 · end of year $1,535,911

  • 11 · Investments: publicly traded securities

    beginning of year $9,761,242 · end of year $31,709,868

  • 12 · Investments: other securities

    beginning of year $0 · end of year $0

  • 13 · Investments: program-related

    beginning of year $0 · end of year $0

  • 14 · Intangible assets

    beginning of year $0 · end of year $0

  • 15 · Other assets

    beginning of year $59,698 · end of year $15,800,086

  • 17 · Accounts payable and accrued expenses

    beginning of year $11,073,526 · end of year $8,012,001

  • 18 · Grants payable

    beginning of year $0 · end of year $0

  • 19 · Deferred revenue

    beginning of year $419,100 · end of year $1,205,080

  • 20 · Tax-exempt bond liabilities

    beginning of year $0 · end of year $0

  • 21 · Escrow or custodial account liability

    beginning of year $0 · end of year $0

  • 22 · Loans and payables to officers and key people

    beginning of year $0 · end of year $0

  • 23 · Secured mortgages and notes payable

    beginning of year $0 · end of year $0

  • 24 · Unsecured notes and loans payable

    beginning of year $0 · end of year $0

  • 25 · Other liabilities

    beginning of year $13,734 · end of year $16,402,910

  • 27 · Net assets without donor restrictions

    beginning of year $165,180,519 · end of year $171,699,550

  • 28 · Net assets with donor restrictions

    beginning of year $0 · end of year $0

Mission and programs · 2023

Mission

TB ALLIANCE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF BETTER, FASTER-ACTING AND AFFORDABLE TUBERCULOSIS DRUGS THAT ARE AVAILABLE TO THOSE WHO NEED THEM.

Activities or mission (Part I)

TO ACCELERATE THE DISCOVERY & DEVELOPMENT OF NEW DRUGS TO FACILITATE THE CONTROL OF TUBERCULOSIS THROUGHOUT THE WORLD AND THE ACCESSIBILITY OF THESE DRUGS TO THE GLOBAL COMMUNITY.

  • RESEARCH AND DEVELOPMENT - TB ALLIANCE IS A NOT-FOR-PROFIT PRODUCT DEVELOPMENT PARTNERSHIP (PDP), UNIQUELY POSITIONED TO LEVERAGE A GLOBAL NETWORK OF PUBLIC AND PRIVATE PARTNERS TO MOST EFFICIENTLY ADVANCE TB DRUG DEVELOPMENT. A PDP BUILDS PARTNERSHIPS BETWEEN THE PUBLIC, PRIVATE, ACADEMIC, AND PHILANTHROPIC SECTORS TO DRIVE THE DEVELOPMENT OF NEW PRODUCTS FOR UNDERSERVED MARKETS. PDPS RETAIN DIRECT MANAGEMENT OVERSIGHT OF THEIR PROJECTS, THOUGH MUCH OF THE LABORATORY AND CLINICAL WORK IS DONE THROUGH EXTERNAL RESEARCH FACILITIES AND CONTRACTORS. WE COMBINE THE RESEARCH AND DEVELOPMENT EXPERTISE OF OUR STAFF WITH THE SKILLS AND RESOURCES OF OUR PARTNERS TO HARNESS THE MOST PROMISING SCIENCE WHEREVER IT MAY EXIST AROUND THE WORLD. THIS MODEL MINIMIZES COSTS, INCLUDING OVERHEAD AND INVESTMENTS IN INFRASTRUCTURE, WHILE OPTIMIZING SCIENTIFIC CAPABILITY TO SPEED NEW TB DRUG DEVELOPMENT. OUR BUSINESS MODEL AND DIVERSE PARTNERSHIPS ALLOW TB ALLIANCE TO LEVERAGE ADDITIONAL PARTNER SERVICES FOR EVERY DOLLAR INVESTED IN ITS PROGRAMS. SIMPLICITB - SIMPLICITB WAS A PHASE III CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF A NOVEL AND POTENTIALLY SHORTER DRUG REGIMEN (BPAMZ) FOR PATIENTS WITH DRUG-SENSITIVE (DS) AND DRUG-RESISTANT (DR) PULMONARY TUBERCULOSIS (SPECIFICALLY MULTIDRUG-RESISTANT TB AND MONO-RESISTANCE TO ISONIAZID OR RIFAMPICIN). THE BPAMZ REGIMEN IS COMPRISED OF FOUR DIFFERENT ANTIMICROBIALS: BEDAQUILINE (B), PRETOMANID (PA), MOXIFLOXACIN (M) AND PYRAZINAMIDE (Z). THE DRUG REGIMEN WAS ADMINISTERED FOR FOUR MONTHS TO PATIENTS WITH DS-TB, AND FOR SIX MONTHS TO PATIENTS WITH MDR-TB OR MONO-RESISTANCE TO RIFAMPICIN OR ISONIAZID. THE RESULTS OF THIS CLINICAL TRIAL WERE PUBLISHED IN LANCET INFECTIOUS DISEASES. SUTEZOLID - SUTEZOLID IS A PROMISING CLINICAL-STAGE TB DRUG CANDIDATE FROM THE OXAZOLIDINONE CLASS. TB ALLIANCE HAS IMPLEMENTED AN OPEN DEVELOPMENT APPROACH TO ADVANCE THE PHASE 2 TB DRUG CANDIDATE, SUTEZOLID, WHICH COULD BE A COMPONENT OF A NEXT-GENERATION TB REGIMEN. TB ALLIANCE HAS MADE SUTEZOLID AVAILABLE FOR STUDY BY ALL RESEARCHERS WHO COMMIT TO MAKING THEIR RESULTS AVAILABLE TO THE BROADER TB RESEARCH COMMUNITY. THIS NOVEL APPROACH HAS CONTRIBUTED TO THREE CLINICAL TRIALS THAT BEGAN IN 2023. NC-009 - NC-009 IS A PAN-PHASE 2 CLINICAL TRIAL INCORPORATING ELEMENTS OF PHASE 2A, B, AND C TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF A NEW EXPERIMENTAL COMPOUND, TBAJ-876, WITH PRETOMANID AND LINEZOLID, COMPONENTS OF TB ALLIANCE'S BPAL REGIMEN. THIS REGIMEN HAS THE POTENTIAL TO SHORTEN AND IMPROVE TREATMENT FOR BOTH DRUG-SENSITIVE AND DRUG-RESISTANT FORMS OF TB. RESULTS FROM PRECLINICAL AND PHASE 1 STUDIES WERE PRESENTED AT THE 2023 UNION CONFERENCE ON LUNG HEALTH AND SHOWED THAT THE NEW COMPOUND, TBAJ-876, WHEN COMPARED WITH BEDAQUILINE (A TB MEDICINE IN THE SAME DRUG CLASS), ELIMINATED TB BACTERIA FASTER AND HAD A POTENTIALLY SAFER PROFILE. NC-009 WILL TEST DIFFERENT DOSES OF TBAJ-876 IN COMBINATION WITH PRETOMANID AND LINEZOLID AGAINST THE CURRENT STANDARD OF CARE FOR DRUG-SENSITIVE TB - ISONIAZID, RIFAMPICIN, PYRAZINAMIDE, AND ETHEMBUTOL (HRZE). ANOTHER ARM OF THE TRIAL WILL ALSO TEST PRETOMANID AND LINEZOLID IN COMBINATION WITH BEDAQUILINE (BPAL), A REGIMEN NOW RECOMMENDED BY THE WORLD HEALTH ORGANIZATION TO TREAT SOME FORMS OF DR-TB, AGAINST DRUG-SENSISTIVE TB. THE STUDY AIMS TO ENROLL 300 PARTICIPANTS WITH DRUG-SENSITIVE TB AT 21 CLINICAL TRIAL SITES IN FIVE COUNTRIES: GEORGIA, PHILIPPINES, SOUTH AFRICA, TANZANIA, AND UGANDA. LIFT-TB (LEVERAGING INNOVATION FOR FASTER TREATMENT OF TB) - THIS ACCESS PROGRAM, LAUNCHED IN 2020, SEEKS TO INCREASE TREATMENT COMPLETION RATES FOR DRUG-RESISTANT TB THROUGH ADOPTION AND SCALE UP OF NEW REGIMENS, BEGINNING WITH BPAL. IT FOCUSES ON SEVEN HIGH-BURDEN SOUTHEAST AND CENTRAL ASIAN COUNTRIES THAT SHOULDER APPROXIMATELY 1 IN 5 OF THE GLOBAL TB CASES. AS OF 2023, MORE THAN 70 COUNTRIES HAVE PROCURED THE SIX-MONTH, ALL-ORAL BPAL REGIMEN TO TREAT MORE THAN 40,000 PEOPLE WITH DRUG-RESISTANT TB. FAST TRACK THE CURE - IN SUPPER OF THE WORLD HEALTH ORGANIZATION'S CALL TO ACTION TO ACCELERATE ACCESS TO SHORTER DR-TB CURES FOR ALL, THE FAST TRACK THE CURE MOVEMENT BRINGS COMMUNITIES AROUND THE WORLD TOGETHER TO RAISE AWARENESS AND FACILITATE ACCESS TO NEW DR-TB TREATMENTS, WHILE RAMPING UP ADVOCACY TO CONVINCE WORLD LEADERS THAT SIX-MONTH DR-TB CURES MUST BE WIDELY ADOPTED AND AVAILABLE TO ALL WHO NEED THEM. FAST TRACK THE CURE IS ALSO COLLABORATING CLOSELY WITH STOP TB TO ENSURE STRATEGIC ALIGNMENT AND PARTNERSHIP AND WITH THE CHALLENGE FACILITY FOR CIVIL SOCIETY MOVEMENT, BY ALIGNING WITH THEIR COMMUNITY ENGAGEMENT, CAPACITY BUILDING, AND DEMAND CREATION PILLARS AND FOCUS. SLASH-TB - TB ALLIANCE AND THE SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE HAVE DEVELOPED SLASH-TB (SAVINGS FROM LEVERAGING & ADOPTING SHORTER & HIGHLY EFFECTIVE TB TREATMENTS), A MODEL TO ESTIMATE COST SAVINGS FOR HEALTH SERVICE SYSTEMS, PATIENTS, FAMILIES, AND/OR CAREGIVERS WHEN USING THE BPAL/M REGIMENS AS COMPARED TO STANDARD DRUG-RESISTANT TB TREATMENTS.

    Expenses $42,131,937

  • PUBLIC AFFAIRS AND POLICY - TB ALLIANCE MAINTAINS CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY FOR THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR ON THE DEVELOPMENT OF THESE MEDICINES. TB ALLIANCE CONTINUES TO PURSUE AN EXPLICIT COMMITMENT TO OUR "AAA MANDATE" - THAT ALL NEW PRODUCTS WILL BE ADOPTED, AVAILABLE AND AFFORDABLE TO THOSE WITH TB.

    Expenses $5,947,379 · Grants $278,450

  • BUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS.

    Expenses $764,217

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Dr Melvin Spigelman

    PRESIDENT/CEO

    Total calculated
    $1,028,783
    From this org
    $921,007
    From related orgs
    $0
    Other
    $107,776
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $640,189
    Bonus
    $280,818
    Other
    $0
    Deferred
    $66,000
    Nontaxable benefits
    $41,776
    Filer's total
    $1,028,783
  • Dr Nader Fotouhi

    SR. VP, CHIEF SCIENTIFIC OFF.

    Total calculated
    $660,036
    From this org
    $545,570
    From related orgs
    $0
    Other
    $114,466
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $426,677
    Bonus
    $118,893
    Other
    $0
    Deferred
    $54,725
    Nontaxable benefits
    $59,741
    Filer's total
    $660,036
  • Dr Eugene Sun

    SR. VP, RESEARCH & DEV'T

    Total calculated
    $648,305
    From this org
    $562,265
    From related orgs
    $0
    Other
    $86,040
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $440,799
    Bonus
    $121,466
    Other
    $0
    Deferred
    $49,168
    Nontaxable benefits
    $36,872
    Filer's total
    $648,305
  • Maria Beumont

    VP, CHIEF MEDICAL OFFICER

    Total calculated
    $564,686
    From this org
    $483,078
    From related orgs
    $0
    Other
    $81,608
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $396,636
    Bonus
    $86,442
    Other
    $0
    Deferred
    $43,500
    Nontaxable benefits
    $38,108
    Filer's total
    $564,686
  • Colleen Pero

    SECRETARY/CAO

    Total calculated
    $525,901
    From this org
    $457,040
    From related orgs
    $0
    Other
    $68,861
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $360,491
    Bonus
    $96,549
    Other
    $0
    Deferred
    $44,970
    Nontaxable benefits
    $23,891
    Filer's total
    $525,901
  • Robert Lorette

    SR. VP, BUSINESS DEVELOPMENT

    Total calculated
    $521,252
    From this org
    $437,313
    From related orgs
    $0
    Other
    $83,939
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $344,453
    Bonus
    $92,860
    Other
    $0
    Deferred
    $42,742
    Nontaxable benefits
    $41,197
    Filer's total
    $521,252
  • Angela Vanderploeg

    TREASURER/CFO

    Total calculated
    $511,320
    From this org
    $411,013
    From related orgs
    $0
    Other
    $100,307
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $321,350
    Bonus
    $89,663
    Other
    $0
    Deferred
    $41,296
    Nontaxable benefits
    $59,011
    Filer's total
    $511,320
  • Sandeep Juneja

    SR. VP, MARKET ACCESS

    Total calculated
    $505,940
    From this org
    $406,262
    From related orgs
    $0
    Other
    $99,678
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $317,751
    Bonus
    $88,511
    Other
    $0
    Deferred
    $40,766
    Nontaxable benefits
    $58,912
    Filer's total
    $505,940
  • Kathleen Schostack

    SR. VP, PROG. & ALLIANCE MGMT

    Total calculated
    $502,947
    From this org
    $419,997
    From related orgs
    $0
    Other
    $82,950
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $329,434
    Bonus
    $90,563
    Other
    $0
    Deferred
    $41,685
    Nontaxable benefits
    $41,265
    Filer's total
    $502,947
  • Salah Foraida

    SR. DIRECTOR, MEDICAL AFFAIRS

    Total calculated
    $469,023
    From this org
    $418,194
    From related orgs
    $0
    Other
    $50,829
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $358,908
    Bonus
    $59,286
    Other
    $0
    Deferred
    $41,771
    Nontaxable benefits
    $9,058
    Filer's total
    $469,023
  • Rajneesh Taneja

    VP, PHARMACEUTICAL PROD. DEV'T

    Total calculated
    $438,718
    From this org
    $360,974
    From related orgs
    $0
    Other
    $77,744
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $295,943
    Bonus
    $65,031
    Other
    $0
    Deferred
    $35,841
    Nontaxable benefits
    $41,903
    Filer's total
    $438,718
  • Pietro Turilli

    SR.VP, EXTERNAL AFFAIRS

    Total calculated
    $419,056
    From this org
    $327,992
    From related orgs
    $0
    Other
    $91,064
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $281,854
    Bonus
    $46,138
    Other
    $0
    Deferred
    $32,689
    Nontaxable benefits
    $58,375
    Filer's total
    $419,056
  • David Norton

    CHAIR

    Total calculated
    $0
    Hours/week
    3
  • Ariel Pablos-Mendez

    VICE CHAIR

    Total calculated
    $0
    Hours/week
    3
  • Eric Goosby

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Rasha Hibri

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Sundar Kodiyalam

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Mario Raviglione

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Kim Schwartz

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Mitchell Warren

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Ratan Watal

    DIRECTOR eff. 1/1/2023

    Total calculated
    $0
    Hours/week
    3

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Independent compensation consultant
  • 3 · Form 990 of other organizations
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 7 · Other non-fixed payments

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 7:
VARIABLE COMPENSATION IS PAID TO STAFF MEMBERS BASED ON ANNUAL PERFORMANCE. SEE SCHEDULE O RESPONSE TO FORM 990, PART VI, SECTION B, LINES 15A AND 15B FOR FURTHER DETAILS.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

Provenance

Return type
form_990
Tax year
2023
Filed
1 October 2024
IRS schema version
2023v5.1
Source object
202412779349301201

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.